Search

Search Constraints

You searched for: Author/Creator Galus, Łukasz

Search Results

1. Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients. Issue 1 (February 2021)

2. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. Issue 5 (October 2020)

3. Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. (19th May 2022)

4. High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. Issue 5 (October 2018)

5. Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment. Issue 3 (3rd June 2023)

6. Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients. (2nd November 2018)